Nishadil
Signup Signin
Delhi | 25°C (windy)
Sarepta's Shares Climb as Critical Safety Study for Elevidys Gene Therapy Kicks Off

Sarepta's Shares Climb as Critical Safety Study for Elevidys Gene Therapy Kicks Off
The Million-Dollar Question: Unpacking the FDA Chief's Gene Therapy Warning

The Million-Dollar Question: Unpacking the FDA Chief's Gene Therapy Warning
The End of an Era: Doug Ingram Prepares to Retire from Sarepta, Elizabeth Barrett Named Successor

The End of an Era: Doug Ingram Prepares to Retire from Sarepta, Elizabeth Barrett Named Successor
A Legal Storm Brews: Sarepta's Groundbreaking Muscular Dystrophy Therapy Faces Renewed Patent Challenge

A Legal Storm Brews: Sarepta's Groundbreaking Muscular Dystrophy Therapy Faces Renewed Patent Challenge
A Vital Step Forward: Sarepta's Duchenne Drug Secures Key Testing Clearance

A Vital Step Forward: Sarepta's Duchenne Drug Secures Key Testing Clearance
The High Stakes Game: Sarepta, Duchenne, and the Edge of Hope

The High Stakes Game: Sarepta, Duchenne, and the Edge of Hope
The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs

The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs
A New Horizon for Duchenne: FDA Approves First Gene Therapy for Life-Threatening Disease in Boys

A New Horizon for Duchenne: FDA Approves First Gene Therapy for Life-Threatening Disease in Boys
Load more..